RNXT - Latest News

RenovoRx, Inc. (RNXT), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $51.8M. Beta to the broader market is 0.97.

The article list below shows the most recent RNXT headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent RNXT Headlines

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

globenewswire.com - Oct 7, 2026

University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection University of Vermont-Sponso

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

globenewswire.com - Oct 1, 2026

Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Un

RenovoRx, Inc. (NASDAQ:RNXT) Stock Short Interest Jumps 55.7%

defenseworld.net - Oct 1, 2026

RenovoRx, Inc. (NASDAQ: RNXT - Get Free Report) saw a large growth in short interest in the month of September.

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

globenewswire.com - Sep 2, 2026

MOUNTAIN VIEW, Calif. , Sept.

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

globenewswire.com - Aug 25, 2026

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial  The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Syst

How News Affects RNXT Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track RNXT's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked RNXT news questions

What is the latest RNXT news headline?

The most recent RNXT headline (Oct 7, 2026) is "RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the RNXT news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What RNXT news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual RNXT options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.